Orion Corporation
Native name
Orion Oyj
TypeJulkinen osakeyhtiö
Nasdaq Helsinki: ORNAV,ORNBV
IndustryPharmaceutical industry
Founded21 September 1917 (1917-09-21)
HeadquartersEspoo, Finland
Key people
Liisa Hurme (President and CEO), Mikael Silvennoinen (Chairman)
ProductsPharmaceuticals and active pharmaceutical ingredients
RevenueDecrease €1.041 billion (2021)
Decrease €243.3 million (2021)
Decrease €193.8 million (2021)
Total assetsDecrease €1.114 billion (2021)
Total equityIncrease €747.9 million (2021)
Number of employees
Increase 3,364 (2021)
Websitewww.orion.fi/en
Footnotes / references
[1]

Orion Corporation (Finnish: Orion Oyj),[2][3] founded in 1917 and headquartered at Espoo, Finland, is a globally operating Finnish company which develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients for global markets. All of the company's manufacturing sites and the majority of its R&D units are in Finland.[4]

Orion's class A and B shares are listed on the Helsinki Stock Exchange.

History

Orion was founded on September 21, 1917 by pharmacists Onni Turpeinen, Eemil Tuurala and Wikki Valkama. Before founding Orion, they worked in a pharmaceutical-chemical factory called Medica. The first premises of the new company were found in a courtyard building in Helsinki's Kruununhaka, Mariankatu 24, i.e. Asunto Oy Mars star. Among the first products of the apothecary were Bellistol gun oil and dulcine.[5] Pediatrician Arvo Ylppö played a significant role starting in the 1920s.[6]

Orion's diagnostics business was previously concentrated in the Orion Diagnostica profit unit, which was sold to a private equity investor in April 2018.[7] The diagnostics business included the development, manufacture and marketing of diagnostic tests and hygiene tests. Orion Diagnostica changed its name in November 2019 and is now Aidian.[8]

Notable products

The following are Orion's top-selling product lines as of March 2021.[9]

Trade name Indication
Stalevo, Comtess, Comtan Parkinson's disease
Easyhaler asthma, COPD
Simdax acute heart failure
dexdor intensive care sedative
Dexdomitor, Domitor, Domosedan, Antisedan animal sedatives
Nubeqa non-metastatic castration-resistant prostate cancer
Solomet inflammation
Divina series menopausal symptoms
Burana inflammatory pain
Marevan anticoagulant

References

  1. ↑ https://www.orion.fi/globalassets/documents/orion-group/investors/interim-reports/2021/en_orion_fy_2021.pdf
  2. ↑ "Orion Oyj". Business Information System. Finnish Patent and Registration Office and Finnish Tax Administration. Retrieved 22 October 2019.
  3. ↑ "Yhtiöjärjestys" [Corporate by-laws] (in Finnish). Espoo: Orion Oyj. 22 March 2017. Retrieved 22 October 2019.
  4. ↑ "About Orion".
  5. ↑ "Orionin virstanpylväitä 1910-luvulla". www.orion.fi. Retrieved 25 July 2022.
  6. ↑ "Orionin vahva mies | Arvo Ylppö". www.ylppo.fi. Retrieved 25 July 2022.
  7. ↑ Moran, Mark (18 May 2018). "AJP Board Member Responds to NYT Story On Antidepressant Withdrawal". Psychiatric News. 53 (10). doi:10.1176/appi.pn.2018.5b14. ISSN 0033-2704.
  8. ↑ "Orion Diagnostica on nyt Aidian". Aidian (in Finnish). Retrieved 25 July 2022.
  9. ↑ https://www.orion.fi/globalassets/documents/orion-group/investors/interim-reports/2021/en_orion_q1_2021_slides.pdf
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.